Jonak, Carrie R.
Pedapati, Ernest V.
Schmitt, Lauren M.
Assad, Samantha A.
Sandhu, Manbir S.
DeStefano, Lisa
Ethridge, Lauren
Razak, Khaleel A.
Sweeney, John A.
Binder, Devin K.
Erickson, Craig A.
Funding for this research was provided by:
National Institutes of Health (U54 HD104461, U54 HD082008)
Article History
Received: 15 October 2021
Accepted: 3 August 2022
First Online: 27 September 2022
Declarations
:
: All human research described in this manuscript was reviewed and approved by the Cincinnati Children’s Hospital Medical Center Institutional Review Board (IRB; IRB reference number 2015-8804). Informed consent was obtained from the guardian of all subjects enrolled in the human subjects research described in this manuscript.All animal research described in this manuscript was approved by the University of California Riverside Institutional Animal Care and Use Committee (IACUC).
: Not applicable.
: CAE and EVP are inventors on a patent(s) that focus on new treatment development in fragile X syndrome held by the Cincinnati Children’s Research Foundation (CCRF) and licensed out at the discretion of CCRF. CAE is a current consultant to Impel, Stalicla, and Scioto Bioscience.